cabazitaxel ever pharma cabazitaxel 60 mg/6 ml concentrated solution for injection vial
interpharma pty ltd - cabazitaxel, quantity: 60 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; macrogol 300; citric acid - cabazitaxel ever pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
cabazitaxel ever pharma cabazitaxel 50 mg/5 ml concentrated solution for injection vial
interpharma pty ltd - cabazitaxel, quantity: 50 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; macrogol 300; citric acid - cabazitaxel ever pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
cabazitaxel ever pharma cabazitaxel 45 mg/4.5 ml concentrated solution for injection vial
interpharma pty ltd - cabazitaxel, quantity: 45 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; macrogol 300; citric acid - cabazitaxel ever pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
cabazitaxel juno cabazitaxel 60 mg/1.5 ml concentrated injection vial
dr reddys laboratories australia pty ltd - cabazitaxel, quantity: 60 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid - cabazitaxel juno in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
cabazitaxel accord cabazitaxel 60 mg/3 ml concentrated injection vial
accord healthcare pty ltd - cabazitaxel, quantity: 60 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute - cabazitaxel accord in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen. .
cabazitaxel winthrop
sanofi-aventis australia pty ltd - cabazitaxel acetone solvate; cabazitaxel; cabazitaxel -
msn cabazitaxel cabazitaxel 60 mg/1.5 ml concentrated injection vial and diluent vial
reach pharmaceuticals pty ltd - cabazitaxel, quantity: 60 mg - injection, diluent for - excipient ingredients: ethanol; water for injections - msn cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
cabazitaxel sanofi
sanofi-aventis australia pty ltd - cabazitaxel acetone solvate; cabazitaxel -
cabazitaxel-teva cabazitaxel 60 mg/6 ml concentrated injection vial
teva pharma australia pty ltd - cabazitaxel ethyl acetate solvate, quantity: 66.32 mg (equivalent: cabazitaxel, qty 60 mg) - injection, concentrated - excipient ingredients: macrogol 400; citric acid; polysorbate 80; ethanol absolute - cabazitaxel-teva in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
cabazitaxel accord
accord healthcare s.l.u. - cabazitaxel - prostatic neoplasms, castration-resistant - antineoplastic agents - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.